Oklahoma Medical Research Foundation Investigators Receive $1.3M for Study of Sarcopenia & Osteoarthritis in Aging Veterans

Two Oklahoma Medical Research Foundation investigators will receive $1 million for aging research including 1) age-related muscle loss and 2) osteoarthritis. There is no cure for either age-related disease.

The Oklahoman reports that the two investigators will receive funds from the U.S. Department of Veteran Affairs.


Holly Van Remmen, Ph.D., chair of OMRF’s aging program, received $650,000 to investigate a possible treatment for age-related muscle loss—known as “Sarcopenia.” A highly relevant problem in the veterans population. It causes muscle weakness and atrophy and no drugs are available to treat this condition.

Van Remmen is working on an investigational sarcopenia therapy called CDN1163, which has shown some success in elderly mice. The investigation included the study of mice until 26-28 months old—equivalent to 70-plus human years. Some of Van Remmen’s findings are published here. Van Remmen hopes to design a more efficient version of CDN1163 then prepare for clinical trials.


Tim Griffin, Ph.D., received $650,000 to study a new clinical approach for people with osteoarthritis, a degenerative joint disease that is a common form of arthritis. With no cure, about half of all Americans develop osteoarthritis (OA) during the course of a lifetime—and it can be very painful. The veteran population has an urgent need for treatments.

Lead Research/Investigators

Holly Van Remmen, Ph.D., chair of OMRF’s aging program

Tim Griffin, Ph.D. Associate Member

Call to Action: Interested in following research about Sarcopenia or Osteoarthritis—focusing on veterans but applicable to all those who are aging? Sign up for the Daily Digest as TrialSite News follows these two investigators’ research.